People think Cheng is a genius, but to me, this guy is more like a snake oil salesman lah! No matter what happens, he always has an explanation ready. His predictions can never be wrong because he keeps changing his story to fit the situation! When the sun comes out, he says the temperature is rising and something big is coming! When it suddenly rains, he says the rain is starting to slow down and things are improving! When the rain gets even heavier, he tells everyone not to panic because sunny days are just around the corner! When the whole place floods, suddenly there’s a deeper meaning that only his followers can understand!Walaooo!

No matter whether it’s sunny, rainy, stormy or flooding, Cheng can always come up with another story to convince his followers that he knows exactly what’s going on!That’s the beauty of snake oil, mah! You don’t need to prove your predictions were right. You just need to sound convincing enough for people to believe you! If the sun comes out, he takes credit. If it rains, he says you misunderstood him. If a typhoon hits, suddenly there’s a bigger picture that ordinary people cannot understand! Ladies and gentlemen, welcome to the greatest show on earth! MASTER CHENG, THE SNAKE OIL SALESMAN

DNAe going through restructuring while Nasdaq listed Celularity regained Nasdaq compliance - FLORHAM PARK, N.J., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) ("Celularity"), a longevity-focused regenerative and cellular medicine company, today announced that it received written confirmation from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") that Celularity has regained compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the U.S. Securities and Exchange Commission. Nasdaq's determination follows Celularity's October 20, 2026 filing of its Quarterly Report on Form 10-Q for the period ended June 30, 2026. Nasdaq confirmed that the reporting deficiency matter is now closed. Revenue was $5.43M for 2Q 2026, down from $5.74M in 2Q 2025 ( (5.3%)).
Net income attributable to common shareholders was $0.55M for 2Q 2026, versus a loss of $24.52M in 2Q 2025 (turnaround YoY).